
The results are published online by Wiley in the American cancer Society's peer-reviewed journal, Cancer.
A news release claims that depression is common among cancer patients. In this phase 2 study, a therapist provided psychological support to 28 patients with major depressive disorder and cancer before, during, and after a single 25 mg dose of psilocybin.
Up to two doses of 25 mg psilocybin are presently being tested against a placebo in a randomised, double-blind experiment to treat anxiety and depression in cancer patients. Building on the single-dose study, this research aims to put the majority of patients in remission from anxiety and depression.
With the goal that psychedelics and psychological support could establish a new standard of therapy for cancer patients with these problems, researchers are now broadening their research to encompass several doses and larger sample sizes.